A once-daily pill for **RELAPSING MULTIPLE SCLEROSIS (MS)**

Take as directed by your doctor if certain liver problems exist.



ZEPOSIA® (ozanimod) 0.92 mg capsules

BE READY FOR WHAT'S NEXT

ZEPOSIA® (ozanimod) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
It is not known if ZEPOSIA is safe and effective in children.

SELECTED IMPORTANT SAFETY INFORMATION

Do not take ZEPOSIA if you:

- have had a heart attack, chest pain (unstable angina), stroke or mini-stroke (transient ischemic attack or TIA), or certain types of heart failure in the last 6 months

This list ("Do not take ZEPOSIA if you:") continues inside.

Bristol Myers Squibb®

Please see Important Safety Information throughout this brochure and full Prescribing Information, including Medication Guide.

ZEPOSIA® (ozanimod) | 0.92 mg capsules

FEWER RELAPSES

with a **ONCE-DAILY** pill

Take as directed by your doctor if certain liver problems exist.

48% FEWER RELAPSES

IN A ONE-YEAR STUDY:
People who took ZEPOSIA® (ozanimod) had **48% fewer relapses** than those who took a leading injectable medicine (Avonex).*†

38% FEWER RELAPSES

IN A SEPARATE TWO-YEAR STUDY:
People who took ZEPOSIA had **38% fewer relapses** than those who took a leading injectable.‡

*Avonex® (interferon beta-1a).

†One-year study: People taking ZEPOSIA had an Annualized Relapse Rate (ARR) of 0.181 vs 0.350 with a leading injectable. A total of 895 people were studied (ZEPOSIA 447, a leading injectable 448).

‡Two-year study: People taking ZEPOSIA had an ARR of 0.172 vs 0.276 with a leading injectable. A total of 874 people were studied (ZEPOSIA 433, a leading injectable 441).

SELECTED IMPORTANT SAFETY INFORMATION

Do not take ZEPOSIA if you (cont'd):

- have or have had a history of certain types of an irregular or abnormal heartbeat (arrhythmia) that is not corrected by a pacemaker
- have untreated, severe breathing problems during your sleep (sleep apnea)
- take certain medicines called monoamine oxidase (MAO) inhibitors (such as selegiline, phenelzine, linezolid)

Talk to your healthcare provider before taking ZEPOSIA if you have any of these conditions or do not know if you have any of these conditions.

Please see Important Safety Information throughout this brochure and full Prescribing Information, including Medication Guide.



What's **inside**

WHY ZEPOSIA **4**
Clinical study results 6
Safety and side effects 12
What MS specialists are saying 14
Taking ZEPOSIA 16
Patient stories about treatment 18

ZEPOSIA SUPPORT **20**
ZEPOSIA 360 Support™ 23

TAKING THE NEXT STEP **24**
Talking to your MS specialist 26

You can find all of this information and more at ZEPOSIA.com/MS



A **once-daily pill** for relapsing MS

Take as directed by your doctor if certain liver problems exist.

Starting any medication is a big decision, so it's important to know the facts and have a discussion with your MS healthcare team about treatment options. In this section, you'll find what you need to know about ZEPOSIA® (ozanimod), including:

- Study results
- Safety and side effects
- Information about taking ZEPOSIA

SELECTED IMPORTANT SAFETY INFORMATION

ZEPOSIA may cause serious side effects, including:

- **Infections.** ZEPOSIA can increase your risk of serious infections that can be life-threatening and cause death. ZEPOSIA lowers the number of white blood cells (lymphocytes) in your blood. This will usually go back to normal within 3 months of stopping treatment. Your healthcare provider may do a blood test of your white blood cells before you start taking ZEPOSIA.

See symptoms of infections on pages 6 and 7.

Please see Important Safety Information throughout this brochure and full Prescribing Information, including Medication Guide.

ZEPOSIA® (ozanimod) 0.92 mg capsules

People had **fewer relapses**

Relapses were studied in people who took ZEPOSIA® (ozanimod) and those who took a leading injectable medicine (Avonex) in two separate clinical studies.* To measure relapses, the Annualized Relapse Rate (ARR) was used, which is the average number of relapses a group of people has in one year.

IN THE ONE-YEAR STUDY:

People who took **ZEPOSIA** had

48% FEWER RELAPSES

than those who took a
LEADING INJECTABLE MEDICINE

People taking ZEPOSIA had an ARR of 0.181 vs 0.350 with a leading injectable. A total of 895 people were in this study (ZEPOSIA 447, a leading injectable 448).

IN A SEPARATE TWO-YEAR STUDY:

38% fewer relapses with ZEPOSIA than with a leading injectable medicine

ARR of 0.172 with ZEPOSIA vs 0.276 with a leading injectable. A total of 874 people were in this study (ZEPOSIA 433, a leading injectable 441).

*Avonex® (interferon beta-1a).

SELECTED IMPORTANT SAFETY INFORMATION

ZEPOSIA may cause serious side effects, including infections (cont'd):

Call your healthcare provider right away if you have any of these symptoms of an infection during treatment with ZEPOSIA and for 3 months after your last dose of ZEPOSIA:

- fever
- feeling very tired
- flu-like symptoms
- cough
- painful and frequent urination (signs of a urinary tract infection)

And more were **relapse free**

The percentage of people who were relapse free was measured in people who took ZEPOSIA and those who took a leading injectable medicine.†

IN THE ONE-YEAR STUDY:

78% of people were RELAPSE FREE with **ZEPOSIA**

VS

66% of people who took a **LEADING INJECTABLE MEDICINE**

IN A SEPARATE TWO-YEAR STUDY:

76% of people who took ZEPOSIA were relapse free

VS

64% of those who took a leading injectable medicine

†A relapse was defined as new or worsening symptoms directly associated with MS that lasted more than twenty-four hours (after having a mostly stable neurological state for at least thirty days).

SELECTED IMPORTANT SAFETY INFORMATION

ZEPOSIA may cause serious side effects, including infections (cont'd):

- rash
- headache with fever, neck stiffness, sensitivity to light, nausea, or confusion (these may be symptoms of meningitis, an infection of the lining around your brain and spine)

Your healthcare provider may delay starting or may stop your ZEPOSIA treatment if you have an infection.

Please see Important Safety Information throughout this brochure and full Prescribing Information, including Medication Guide.

ZEPOSIA® (ozanimod) 0.92 mg capsules

Fewer new or enlarging **lesions (T2)**

The number of new or enlarging lesions (T2) was measured in people who took ZEPOSIA® (ozanimod) and those who took a leading injectable medicine (Avonex)* in both clinical studies.

T2 (lesions) refers to a type of magnetic resonance imaging (MRI) scan that can be used to identify the total number of lesions a person has.

IN THE ONE-YEAR STUDY:

48% FEWER **new or enlarging lesions (T2)** with **ZEPOSIA** than a leading injectable medicine

ZEPOSIA AT ONE YEAR

LEADING INJECTABLE MEDICINE AT ONE YEAR

People taking ZEPOSIA had an average of 1.47 lesions vs 2.84 with a leading injectable.

IN A SEPARATE TWO-YEAR STUDY:

42% fewer new or enlarging lesions (T2) with ZEPOSIA than with a leading injectable medicine

An average of 1.84 lesions (T2) with ZEPOSIA vs 3.18 with a leading injectable.

*Avonex® (interferon beta-1a).

SELECTED IMPORTANT SAFETY INFORMATION

ZEPOSIA may cause serious side effects, including (cont'd):

- **Progressive multifocal leukoencephalopathy (PML).** ZEPOSIA can increase your risk for PML, which is a rare brain infection that usually leads to death or severe disability. If PML happens, it usually happens in people with weakened immune systems but has happened in people who do not have weakened immune systems. Symptoms of PML get worse over days to weeks.

Fewer lesions showing **active inflammation (T1)**

T1 Gadolinium (Gd)-enhancing lesions are areas of active inflammation that show current MS activity in the brain. These lesions were also measured in both of the clinical studies.

IN THE ONE-YEAR STUDY:

63% FEWER **T1 Gd-enhancing lesions** with **ZEPOSIA** than a leading injectable medicine

ZEPOSIA AT ONE YEAR

LEADING INJECTABLE MEDICINE AT ONE YEAR

People taking ZEPOSIA had an average of 0.16 lesions (T1 Gd-enhancing) vs 0.43 with a leading injectable.

IN A SEPARATE TWO-YEAR STUDY:

53% fewer T1 Gd-enhancing lesions with ZEPOSIA than a leading injectable medicine

An average of 0.18 lesions (T1 Gd-enhancing) vs 0.37 with a leading injectable.

SELECTED IMPORTANT SAFETY INFORMATION

ZEPOSIA may cause serious side effects, including PML (cont'd):

Call your doctor right away if you have any new or worsening symptoms of PML that have lasted several days, including: weakness on one (1) side of your body, changes in your vision, changes in your thinking or memory, confusion, changes in your personality, loss of coordination in your arms or legs, decreased strength, and/or problems with balance.

Please see Important Safety Information throughout this brochure and full Prescribing Information, including Medication Guide.

ZEPOSIA® (ozanimod) 0.92 mg capsules

Measuring **disability progression**

Both clinical studies measured physical disability progression every three months in people who took ZEPOSIA® (ozanimod) and those who took a leading injectable medicine, Avonex® (interferon beta-1a).

When taking ZEPOSIA or Avonex,
9 out of **10** people experienced

NO CONFIRMED PROGRESSION OF PHYSICAL DISABILITY
(as defined in studies)

THERE WAS NO SIGNIFICANT DIFFERENCE
in disability progression between people who took ZEPOSIA (7.6% of people) and those who took a leading injectable medicine (7.8% of people).

This progression was confirmed after 3 months with predefined increases in Expanded Disability Status Scale scores and results were combined from both clinical studies.

SELECTED IMPORTANT SAFETY INFORMATION

ZEPOSIA may cause serious side effects, including (cont'd):

- **Slow heart rate (also known as bradyarrhythmia) when you start taking ZEPOSIA.** ZEPOSIA may cause your heart rate to temporarily slow down, especially during the first 8 days. You will have a test to check the electrical activity of your heart called an electrocardiogram (ECG) before you take your first dose of ZEPOSIA.

About the **clinical studies**

The two clinical studies for ZEPOSIA, when combined, were one of the largest studies to compare one MS medication to another (not a placebo). Together, the two studies included 1,769 people: ZEPOSIA 880, a leading injectable medicine 889.

WHO WAS STUDIED:

The average age across both studies was
35½ YEARS OLD

In both studies combined, approximately
65% WERE FEMALE

How does ZEPOSIA work? Watch to find out.
See how ZEPOSIA is thought to treat MS ›

Please see Important Safety Information throughout this brochure and full Prescribing Information, including Medication Guide.

ZEPOSIA® (ozanimod) 0.92 mg capsules

Safety and side effects

With any treatment, it's important to know what side effects are possible. The safety and side effects of ZEPOSIA® (ozanimod) were evaluated in 882 people during two clinical studies.

90% of people taking ZEPOSIA remained on treatment throughout the clinical studies.
Of those who stopped taking ZEPOSIA, 3% did so because of a side effect they experienced. The rest left the studies for a variety of other reasons.

POSSIBLE SERIOUS SIDE EFFECTS

These are the serious side effects reported by people who took ZEPOSIA during the clinical studies:

- Infections that can be life-threatening and cause death
- Progressive multifocal leukoencephalopathy (PML)
- Slow heart rate
- Liver problems
- Increased blood pressure
- Breathing problems (ie, shortness of breath)
- Macular edema (a vision problem)
- Swelling and narrowing of blood vessels in your brain
- Severe worsening of MS after stopping ZEPOSIA compared to before or during treatment

To learn more about the symptoms associated with these side effects, please see the Important Safety Information beginning on page 28.

MOST COMMON SIDE EFFECTS

During both of the clinical studies, people who took ZEPOSIA were asked to report any side effects that they experienced. These were the most common:

- Upper respiratory tract infections
- Elevated liver enzymes
- Low blood pressure upon standing
- Painful and frequent urination
- Back pain
- High blood pressure
- Headache

Visit ZEPOSIA.com/side-effects to see the percentages of those who experienced these side effects with ZEPOSIA and with a leading injectable medicine, Avonex® (interferon beta-1a).

These are not all of the side effects of ZEPOSIA. Please see the Prescribing Information for information on all of the side effects reported by those taking ZEPOSIA. If you experience any side effects while taking ZEPOSIA, be sure to talk to your doctor right away.

Please see Important Safety Information throughout this brochure and full Prescribing Information, including Medication Guide.

ZEPOSIA® (ozanimod) 0.92 mg capsules

What **MS specialists** are saying

Healthcare professionals who have prescribed ZEPOSIA® (ozanimod) to their patients with relapsing MS have been sharing their experiences. Here is some of what they've had to say.

PATIENTS ARE SEEING RESULTS

*"My patients are **excited with the clinical results** seen in studies and the process of getting started with ZEPOSIA."*

– Patricia Pagnotta, APRN, MSCN
MS Center of Greater Orlando*

*"**I recommend ZEPOSIA because it has proven effectiveness.** The fact that it was compared to another FDA-approved MS medication in a large study sets the bar high."*

– Bruce Hughes, MD
FAAN Medical Director,
MercyOne Neurosciences*

*Paid consultant of Bristol Myers Squibb.

Please see Important Safety Information throughout this brochure and full Prescribing Information, including Medication Guide.

ABOUT TAKING ZEPOSIA

*"A once-daily† pill is great for my patients. Many of them travel, and **to have an option that doesn't need to be refrigerated is great.**"*

– Ann Cabot, DO
Director of Specialty MS Care Clinic
Concord Hospital*

†Take as directed by your doctor if certain liver problems exist.

Customize your own Doctor Discussion Guide

Answer a few questions, then bring your personalized guide to your next MS visit.

Get started ›

SELECTED IMPORTANT SAFETY INFORMATION

ZEPOSIA may cause serious side effects, including slow heart rate (cont'd):

Call your healthcare provider if you experience the following symptoms of slow heart rate:

- dizziness
- lightheadedness
- feeling like your heart is beating slowly or skipping beats
- shortness of breath
- confusion
- chest pain
- tiredness

Follow directions from your healthcare provider when starting ZEPOSIA and when you miss a dose.

ZEPOSIA® (ozanimod) 0.92 mg capsules

A **once-daily pill**

Take as directed by your doctor if certain liver problems exist.



ZEPOSIA® (ozanimod) is a once-daily pill that can be taken when and where you want. If you have certain liver problems, take as directed by your healthcare provider.

- Take it with or without food
- ZEPOSIA doesn't need to be refrigerated

A few steps before you get started

Before you can begin taking ZEPOSIA, some routine testing is required:

- **Blood work**—including complete blood count and liver function test
- **An electrocardiogram (ECG)**—a common test that uses small sensors to monitor your heart and makes sure it's working normally before you start treatment
- **An eye exam**—this may only be required for people with a history of macular edema, uveitis, or diabetes

These tests can be completed at your home if you're eligible and commercially insured. ZEPOSIA 360 Support™ can help schedule them.*

SELECTED IMPORTANT SAFETY INFORMATION

ZEPOSIA can cause serious side effects, including:

- **liver problems.** Your healthcare provider will do blood tests to check your liver before you start taking ZEPOSIA. Call your healthcare provider right away if you have any of the following symptoms:
  - unexplained nausea
  - vomiting
  - stomach area (abdominal) pain
  - tiredness
  - loss of appetite
  - yellowing of the whites of your eyes or skin
  - dark colored urine

Getting **started**

Once you've been approved to begin treatment, you'll receive the **ZEPOSIA Starter Kit**.† It will either be provided to you by your healthcare team or delivered directly to your home.

- **A 7-day Starter Pack** for your first week of treatment. The pills in this pack help increase your dosage of ZEPOSIA gradually. Each pill is labeled with the day and dosage. Be sure to follow the instructions written on the pack and take the pills in the correct order
- **The regular dosage of ZEPOSIA** (orange capsules) you'll begin taking on day 8 (after completing the 7-day Starter Pack)

It's important to take ZEPOSIA exactly as prescribed by your MS healthcare team.

*Patient must have a valid prescription for ZEPOSIA for an FDA-approved indication. Patients are not eligible if they have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPUS, TRICARE, Veterans Affairs (VA), or Department of Defense (DoD) programs, or reside in Rhode Island. To receive the In-Home Medical Services Program, the prescriber must request in-home assessment assistance through the ZEPOSIA 360 Support program. The patient's insurance will not be billed, and the patient will not be responsible for any out-of-pocket costs. Patients who move from commercial plans to state or federal healthcare programs will no longer be eligible. The program cannot be combined with any other offer, rebate, coupon, or free trial. The program is not conditioned on any past, present, or future purchase, including refills. Only valid in the United States and US Territories. Void where prohibited by law, taxed, or restricted. The program is not insurance. Bristol-Myers Squibb Company reserves the right to rescind, revoke, or amend this program at any time without notice. Other limitations may apply.

†Patient must have a valid prescription for ZEPOSIA for an FDA-approved indication. Patient must be new to therapy and have not previously received a sample or filled a prescription for ZEPOSIA. Patient is responsible for applicable taxes, if any. This offer is limited to one use per patient per lifetime and is non-transferable. Cannot be combined with any other rebate/coupon, free trial, or similar offer. No substitutions permitted. Patients, pharmacists, and prescribers cannot seek reimbursement for the ZEPOSIA Free Trial from health insurance or any third party, including state or federally funded programs. Patients may not count the ZEPOSIA Free Trial as an expense incurred for purposes of determining out-of-pocket costs for any plan, including Medicare Part D true out-of-pocket costs (TrOOP). Offer is not conditioned on any past, present, or future purchase, including refills. Only valid in the United States and US Territories. Void where prohibited by law or restricted. The program is not insurance. Bristol Myers Squibb reserves the right to rescind, revoke, or amend this offer at any time without notice.

Please see Important Safety Information throughout this brochure and full Prescribing Information, including Medication Guide.

ZEPOSIA® (ozanimod) 0.92 mg capsules

Patient stories
about treatment

If you're considering moving forward with ZEPOSIA® (ozanimod), it can help to hear from someone who's been there. Take a peek into the unique stories of real people taking ZEPOSIA for relapsing multiple sclerosis (MS).

*"There can be a lot of challenges with having MS, but **ZEPOSIA helps me keep moving forward**."*

– Deina*
Yogi and devoted aunt

*"I'd heard a lot about ZEPOSIA, so I mentioned it to my doctor, and she decided it was a good choice for me. It's been over a year now, and **it's working well for me**. My doctor is happy with the results."*

– Melissa*
Educator and cycling enthusiast
(Individual results may vary.)

Hear their stories ›

*Actual ZEPOSIA patients compensated for their time.

Please see Important Safety Information throughout this brochure and full Prescribing Information, including Medication Guide.

*"When I was diagnosed, I learned a lot about MS very quickly. I also researched and read everything about ZEPOSIA and the 360 Support program, which **was very helpful to me**."*

– Kathleen*
Corporate executive and world traveler

*"The Support Coordinator worked with my specialty pharmacy to arrange **delivery of ZEPOSIA directly to my home**, which works great for me."*†

– Omar*
Radio host and voiceover artist

†While Support Coordinators can answer questions about ZEPOSIA 360 Support™, they cannot provide medical advice.

SELECTED IMPORTANT SAFETY INFORMATION

ZEPOSIA can cause serious side effects, including (cont'd):

- **a problem with your vision called macular edema.** Your risk of macular edema is higher if you have diabetes or have had an inflammation of your eye called uveitis. Your healthcare provider should test your vision before you start taking ZEPOSIA if you are at higher risk for macular edema or any time you notice vision changes during treatment with ZEPOSIA. Call your healthcare provider right away if you have any of the following symptoms:
  - blurriness or shadows in the center of your vision
  - sensitivity to light
  - a blind spot in the center of your vision
  - unusually colored vision

ZEPOSIA® (ozanimod) 0.92 mg capsules



ZEPOSIA® (ozanimod) is for adults.

ZEPOSIA (ozanimod) 0.92 mg capsules 360 SUPPORT™

Supporting you **every step of the way**

ZEPOSIA 360 Support™ has materials and resources designed to help you get the support you need, whether you're considering ZEPOSIA or already getting started with treatment.

I'm considering ZEPOSIA:
ZEPOSIA 360 Support has information that can help you find out if ZEPOSIA may be right for you.

If you're taking ZEPOSIA or are about to start:
When you begin treatment with ZEPOSIA, you'll have support available to you at every step of the way. A dedicated Support Coordinator can help determine your coverage for ZEPOSIA, what your out-of-pocket costs may be, and other financial options.

See the next page for details of the program.

Please see Important Safety Information throughout this brochure and full Prescribing Information, including Medication Guide.

ZEPOSIA® (ozanimod) 0.92 mg capsules

Just some of the **support that's available**

Support Coordinators

If you've been prescribed ZEPOSIA, a Support Coordinator can help answer questions about your insurance coverage and support options.

Our Support Coordinators are available to help.

Contact ZEPOSIA 360 Support™
at 1-833-ZEPOSIA (1-833-937-6742)
Monday to Friday, 8 AM–8 PM ET.

*Data provided by Bristol Myers Squibb and is current as of December 2022.
†ZEPOSIA Co-pay Program is valid only for patients with commercial insurance. The Program includes a prescription benefit offer for out-of-pocket drug costs and a medical assessment benefit offer for out-of-pocket costs for the initial blood tests, ECG screening, and eye exam where the full cost is not covered by patient's insurance. Patients are not eligible for the prescription benefit offer if they have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPUS, TRICARE, Veterans Affairs (VA), or Department of Defense (DoD) programs. Patients are not eligible for the medical assessment benefit offer if they have insurance coverage for their prescription or medical assessment through a state or federal healthcare program, or reside in Massachusetts, Minnesota or Rhode Island. Patients who move from commercial plans to state or federal healthcare programs will no longer be eligible. Patient must be 18 years of age or older. Eligible patients with an activated co-pay card and a valid prescription may pay as little as $0 per 30-day supply; monthly, annual, and/or per-claim maximum program benefits may apply and vary from patient to patient, depending on the terms of a patient's prescription drug plan and to ensure that the funds are used for the benefit of the patient, based on factors determined solely by Bristol-Myers Squibb. Some prescription drug plans have established programs referred to as "co-pay maximizer" programs. A co-pay maximizer program is one in which the amount of the patient's out-of-pocket costs is adjusted to reflect the availability of support offered by a co-pay support program. Patients enrolled in co-pay maximizer programs may receive program benefits that vary over time to ensure the program funds are used for the benefit of the patient. Patients may pay as little as $0 in out-of-pocket costs for the medical assessment, subject to a maximum benefit of $2,000. The medical benefit offer only applies to clinical baseline assessment services covered by the Program. Patients are responsible for any costs that exceed the maximum amounts. To receive the medical assessment benefit, an Explanation of Benefits (EOB) form must be submitted, along with copies of receipts for any payments made. The Program expires on December 31, 2023. All Program payments are for the benefit of the patient only. Patients, pharmacists, and prescribers may not seek reimbursement from health insurance, health savings or flexible spending accounts, or any third party, for any part of the prescription or medical assessment benefit received by the patient through this Program. Patient's acceptance of any Program benefit confirms that it is consistent with patient's insurance and that patient will report the value received as may be required by his/her insurance provider. Program valid only in the United States and Puerto Rico. Void where prohibited by law, taxed, or restricted. The Program cannot be combined with any other offer, rebate, coupon, or free trial. The Program is not conditioned on any past, present or future purchase, including refills. The Program is not insurance. Other limitations may apply. Bristol Myers Squibb reserves the right to rescind, revoke, or amend this Program at any time without notice.
‡Please see full Bridge Program terms and conditions on page 25.

ZEPOSIA (ozanimod) 0.92 mg capsules | 360 SUPPORT™

Financial support

Depending on your insurance coverage and financial needs, there may be several different ways to save on the cost of ZEPOSIA and the tests needed before treatment. Our Support Coordinators can help you understand your options.

ZEPOSIA is covered for over 90% of people with private or commercial health insurance.*

There are many ways to save on treatment costs, including:

- **A co-pay offer** that may help those who are eligible and commercially insured pay as little as $0 a month for ZEPOSIA†
- **Reimbursement for medical costs** associated with appointments or routine tests before starting ZEPOSIA, for eligible, commercially insured patients†
- **The ZEPOSIA Bridge Program** may provide help for eligible, commercially insured patients who are experiencing a delay in obtaining coverage or have been denied coverage‡

We'll keep you updated and informed

By signing up for ZEPOSIA 360 Support communications, you'll receive the latest information sent directly to you, including:

- **Information** about ZEPOSIA
- **A guide** for talking to your MS healthcare team
- **Stories** from real people taking ZEPOSIA
- **A brochure** with additional information

Sign up for more ZEPOSIA 360 Support

Please see Important Safety Information throughout this brochure and full Prescribing Information, including Medication Guide.



Having a **focused** conversation

The next step in any treatment decision is to speak with your MS healthcare team to make sure you have the answers you need.

Find 7 key questions you can ask your MS specialist **on the next page**.

Bridge Program terms and conditions
The Bridge Program is available at no cost for eligible, commercially insured, on-label diagnosed patients if there is a delay in determining whether commercial prescription coverage is available, and is not contingent on any purchase requirement, for up to 24 months (dispensed in 30-day increments). The Bridge Program is not available to patients who have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPUS, TRICARE, Veterans Affairs (VA), or Department of Defense (DoD) programs and is available for no more than 12 months to patients in MA, MN, and RI. Appeal of any prior authorization denial must be made within 90 days or as per payer guidelines, to remain in the program. Eligibility will be re-verified in January for patients continuing into the following year, and may be at other times during program participation. Offer is not health insurance. Once coverage is approved by the patient's commercial insurance plan, the patient will no longer be eligible. Void where prohibited by law, taxed, or restricted. Bristol-Myers Squibb Company reserves the right to rescind, revoke, or amend this program at any time without notice. Other limitations may apply.

SELECTED IMPORTANT SAFETY INFORMATION

ZEPOSIA can cause serious side effects, including (cont'd):

- **swelling and narrowing of the blood vessels in your brain.** Posterior Reversible Encephalopathy Syndrome (PRES) is a rare condition that has happened with ZEPOSIA and with drugs in the same class. Symptoms of PRES usually get better when you stop taking ZEPOSIA. If left untreated, it may lead to stroke. Your healthcare provider will do a test if you have any symptoms of PRES. Call your healthcare provider right away if you have any of the following symptoms:
  - sudden severe headache
  - sudden confusion
  - sudden loss of vision or other changes in your vision
  - seizure

Please see Important Safety Information throughout this brochure and full Prescribing Information, including Medication Guide.

ZEPOSIA® (ozanimod) | 0.92 mg capsules

7 questions to ask your healthcare team

The time you have with your healthcare team is extremely valuable. Being prepared with questions can help keep the conversation focused—and allow you to get the answers you need. To learn more about ZEPOSIA® (ozanimod), here are some questions you might consider asking:

1 **What impact could ZEPOSIA have on my relapses and lesions?**

2 **What should I know about physical disability progression and taking ZEPOSIA?**

3 **What are the most common side effects of ZEPOSIA?**

4 **How is ZEPOSIA taken, and how often?**

5 **What do I need to know about getting started with ZEPOSIA?**

6 **How does ZEPOSIA work?**

7 **Is ZEPOSIA a good fit for me?**

Please see Important Safety Information throughout this brochure and full Prescribing Information, including Medication Guide.

INDICATION

ZEPOSIA® (ozanimod) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
It is not known if ZEPOSIA is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not take ZEPOSIA if you:

- have had a heart attack, chest pain (unstable angina), stroke or mini-stroke (transient ischemic attack or TIA), or certain types of heart failure in the last 6 months
- have or have had a history of certain types of an irregular or abnormal heartbeat (arrhythmia) that is not corrected by a pacemaker
- have untreated, severe breathing problems during your sleep (sleep apnea)
- take certain medicines called monoamine oxidase (MAO) inhibitors (such as selegiline, phenelzine, linezolid)

Talk to your healthcare provider before taking ZEPOSIA if you have any of these conditions or do not know if you have any of these conditions.

ZEPOSIA may cause serious side effects, including:

- **Infections.** ZEPOSIA can increase your risk of serious infections that can be life-threatening and cause death. ZEPOSIA lowers the number of white blood cells (lymphocytes) in your blood. This will usually go back to normal within 3 months of stopping treatment. Your healthcare provider may do a blood test of your white blood cells before you start taking ZEPOSIA.

  Call your healthcare provider right away if you have any of these symptoms of an infection during treatment with ZEPOSIA and for 3 months after your last dose of ZEPOSIA:

  - fever
  - feeling very tired
  - flu-like symptoms
  - cough
  - painful and frequent urination (signs of a urinary tract infection)
  - rash
  - headache with fever, neck stiffness, sensitivity to light, nausea, or confusion (these may be symptoms of meningitis, an infection of the lining around your brain and spine)

  Your healthcare provider may delay starting or may stop your ZEPOSIA treatment if you have an infection.

- **Progressive multifocal leukoencephalopathy (PML).** ZEPOSIA can increase your risk for PML, which is a rare brain infection that usually leads to death or severe disability. If PML happens, it usually happens in people with weakened immune systems but has happened in people who do not have weakened immune systems. Symptoms of PML get worse over days to weeks. Call your doctor right away if you have any new or worsening symptoms of PML that

IMPORTANT SAFETY INFORMATION (cont'd)

have lasted several days, including: weakness on one (1) side of your body, changes in your vision, changes in your thinking or memory, confusion, changes in your personality, loss of coordination in your arms or legs, decreased strength, and/or problems with balance.

- **Slow heart rate (also known as bradyarrhythmia) when you start taking ZEPOSIA.** ZEPOSIA may cause your heart rate to temporarily slow down, especially during the first 8 days. You will have a test to check the electrical activity of your heart called an electrocardiogram (ECG) before you take your first dose of ZEPOSIA.
  Call your healthcare provider if you experience the following symptoms of slow heart rate:

  - dizziness
  - lightheadedness
  - feeling like your heart is beating slowly or skipping beats
  - shortness of breath
  - confusion
  - chest pain
  - tiredness

Follow directions from your healthcare provider when starting ZEPOSIA and when you miss a dose.

Continue reading for additional possible serious side effects of ZEPOSIA.

Before taking ZEPOSIA, tell your healthcare provider about all of your medical conditions, including if you:

- have a fever or infection, or are unable to fight infections due to a disease, or take or have taken medicines that lower your immune system
- received a vaccine in the past 30 days or are scheduled to receive a vaccine. ZEPOSIA may cause vaccines to be less effective
- before you start ZEPOSIA, your healthcare provider may give you a chickenpox (Varicella Zoster Virus) vaccine if you have not had one before
- have had chickenpox or have received the vaccine for chickenpox. Your healthcare provider may do a blood test for the chickenpox virus. You may need to get the full course of the vaccine and wait 1 month before taking ZEPOSIA
- have a slow heart rate
- have an irregular or abnormal heartbeat (arrhythmia)
- have a history of stroke
- have or have had heart problems, including a heart attack or chest pain
- have high blood pressure
- have liver problems
- have breathing problems, including during your sleep
- have eye problems, especially an inflammation of the eye called uveitis

Please see Important Safety Information throughout this brochure and full Prescribing Information, including Medication Guide.

ZEPOSIA® (ozanimod) 0.92 mg capsules

IMPORTANT SAFETY INFORMATION (cont'd)

Before taking ZEPOSIA, tell your healthcare provider about all of your medical conditions, including if you (cont'd):

- have diabetes
- are or plan to become pregnant or if you become pregnant within 3 months after you stop taking ZEPOSIA. ZEPOSIA may harm your unborn baby. If you are a female who can become pregnant, talk to your healthcare provider about what birth control method is right for you during your treatment with ZEPOSIA and for 3 months after you stop taking ZEPOSIA. If you become pregnant while taking ZEPOSIA, tell your healthcare provider right away and enroll in the ZEPOSIA Pregnancy Registry by calling 1-877-301-9314 or visiting www.zeposiapregnancyregistry.com
- are breastfeeding or plan to breastfeed. It is not known if ZEPOSIA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take ZEPOSIA

Tell your healthcare provider about all the medicines you take or have recently taken, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using ZEPOSIA with other medicines can cause serious side effects. Especially tell your healthcare provider if you take or have taken:

- medicines that affect your immune system, such as alemtuzumab
- medicines to control your heart rhythm (antiarrhythmics), or heartbeat
- CYP2C8 inducers such as rifampin
- CYP2C8 inhibitors such as gemfibrozil (medicine to treat high fat in your blood)
- opioids (pain medicine), medicines to treat depression, and medicines to treat Parkinson's disease
- medicines to control your heart rate and blood pressure (beta blocker medicines and calcium channel blocker medicines)

You should not receive **live** vaccines during treatment with ZEPOSIA, for at least 1 month before taking ZEPOSIA and for 3 months after you stop taking ZEPOSIA. Vaccines may not work as well when given during treatment with ZEPOSIA.

ZEPOSIA can cause serious side effects, including:

- **liver problems.** Your healthcare provider will do blood tests to check your liver before you start taking ZEPOSIA. Call your healthcare provider right away if you have any of the following symptoms:
  - unexplained nausea
  - vomiting
  - stomach area (abdominal) pain
  - tiredness
  - loss of appetite
  - yellowing of the whites of your eyes or skin
  - dark colored urine
- **increased blood pressure.** Your healthcare provider should check your blood pressure during treatment with ZEPOSIA. A sudden, severe increase in blood pressure (hypertensive crisis) can happen when you eat certain foods that contain high levels of tyramine.

IMPORTANT SAFETY INFORMATION (cont'd)

- **breathing problems.** Some people who take ZEPOSIA have shortness of breath. Call your healthcare provider right away if you have new or worsening breathing problems.
- **a problem with your vision called macular edema.** Your risk of macular edema is higher if you have diabetes or have had an inflammation of your eye called uveitis. Your healthcare provider should test your vision before you start taking ZEPOSIA if you are at higher risk for macular edema or any time you notice vision changes during treatment with ZEPOSIA. Call your healthcare provider right away if you have any of the following symptoms:
  - blurriness or shadows in the center of your vision
  - sensitivity to light
  - a blind spot in the center of your vision
  - unusually colored vision
- **swelling and narrowing of the blood vessels in your brain.** Posterior Reversible Encephalopathy Syndrome (PRES) is a rare condition that has happened with ZEPOSIA and with drugs in the same class. Symptoms of PRES usually get better when you stop taking ZEPOSIA. If left untreated, it may lead to stroke. Your healthcare provider will do a test if you have any symptoms of PRES. Call your healthcare provider right away if you have any of the following symptoms:
  - sudden severe headache
  - sudden confusion
  - sudden loss of vision or other changes in your vision
  - seizure
- **severe worsening of multiple sclerosis (MS) after stopping ZEPOSIA.** When ZEPOSIA is stopped, symptoms of MS may return and become worse compared to before or during treatment. Always talk to your healthcare provider before you stop taking ZEPOSIA for any reason. Tell your healthcare provider if you have worsening symptoms of MS after stopping ZEPOSIA.

The most common side effects of ZEPOSIA can include:

- upper respiratory tract infections
- elevated liver enzymes
- low blood pressure when you stand up (orthostatic hypotension)
- painful and frequent urination (signs of urinary tract infection)
- back pain
- high blood pressure
- headache

These are not all of the possible side effects of ZEPOSIA. For more information, ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

ZEPOSIA® (ozanimod) | 0.92 mg capsules

Please see full Prescribing Information, including Medication Guide.

ZEPOSIA® (ozanimod) | 0.92 mg capsules



Inside:

7 questions to ask your healthcare team about ZEPOSIA

We're with you every step of the way.*

Contact ZEPOSIA 360 Support™ at
1-833-ZEPOSIA (1-833-937-6742)
Monday to Friday, 8 AM–8 PM ET.

*While Support Coordinators can answer questions about ZEPOSIA 360 Support, they cannot provide medical advice.

Like us on **Facebook**
@ZEPOSIA

Follow us on **Instagram**
@ZEPOSIA_ozanimod

2084-US-2301238 10/23

Bristol Myers Squibb®